Ono M, Izumi H, Yoshida S, Goto D, Jimi S, Kawahara N, Shono T, Ushiro S, Ryuto M, Kohno K, Sato Y, Kuwano M
Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.
Cancer Chemother Pharmacol. 1996;38 Suppl:S78-82. doi: 10.1007/s002800051044.
Neovascularization is often required for rapid growth of solid tumors and also limits vascular metastasis of tumor cells. Neovascularization-targeting agents are a recent innovation that may be a novel means of anticancer therapy. These antiangiogenic drugs have been developed by targeting cell proliferation of vascular endothelial cells, basement-membrane-degrading enzymes, angiogenic factors/receptors, extracellular matrix, angiogenesis signaling, and cell-cell/cell-matrix interactions. In this report, we describe how tumor angiogenesis occurs and how antiangiogenic agents are developed.
实体瘤的快速生长通常需要新血管生成,同时新血管生成也限制了肿瘤细胞的血管转移。靶向新血管生成的药物是一项最新创新,可能是一种新型抗癌治疗手段。这些抗血管生成药物是通过靶向血管内皮细胞的细胞增殖、基底膜降解酶、血管生成因子/受体、细胞外基质、血管生成信号以及细胞-细胞/细胞-基质相互作用而研发出来的。在本报告中,我们描述了肿瘤血管生成是如何发生的以及抗血管生成药物是如何研发的。